Who is affected by this change?

This affects Independence Blue Cross Oncology providers on Medicare Advantage plans.

When does this change take effect?

This change is effective Nov 26, 2025.

Back to dashboard

Medicare AdvantageCoverageMedium impact

MA08.143b, Tebentafusp-tebn (Kimmtrak®)

Independence Blue Cross·Oncology·Pharmacy

Effective date

Nov 26, 2025

We identified it

Jun 19, 2026

Days to comply

—

Summary

Medicare Advantage policy MA08.143b for Tebentafusp-tebn (Kimmtrak®) has been reissued with updates effective November 26, 2025. This is a pharmacy policy change affecting coverage or authorization requirements for this oncology medication used to treat uveal melanoma.

Action Required

Action needed

By November 26, 2025: Review updated policy MA08.143b for Tebentafusp-tebn (Kimmtrak®) at the provided URL to understand specific coverage changes. Oncology billing team should verify current prior authorization requirements and update protocols for Medicare Advantage patients requiring this medication.

Related policy hubs

Independence Blue Cross policies Oncology